How race and ancestry influence breast cancer treatment responses
Race and ancestry as predictors of the tumor immune microenvironment and response to immunotherapy
This study is looking at how different racial and ethnic backgrounds influence how well women with triple-negative breast cancer respond to immunotherapy, aiming to understand treatment differences among Black, Hispanic/Latina, and Asian women to help improve care for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10880147 on NIH RePORTER |
What this research studies
This research investigates how different racial and ethnic backgrounds affect the immune response to breast cancer treatments, particularly immunotherapy. It focuses on understanding the tumor immune microenvironment in women with triple-negative breast cancer (TNBC), a type that is more responsive to these treatments. By analyzing population-based cancer registry data, the study aims to determine the frequency of immunotherapy use among diverse groups, including Black, Hispanic/Latina, and Asian women. The goal is to uncover disparities in treatment outcomes and improve personalized care for these populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include women diagnosed with triple-negative breast cancer, particularly those from Black, Hispanic/Latina, and Asian backgrounds.
Not a fit: Patients with non-breast cancer diagnoses or those not belonging to the specified racial and ethnic groups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored immunotherapy treatments for breast cancer patients from diverse racial and ethnic backgrounds.
How similar studies have performed: Previous research has indicated that understanding the tumor immune microenvironment can significantly impact treatment outcomes, suggesting that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ziv, Elad — University of California, San Francisco
- Study coordinator: Ziv, Elad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.